Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

William Blair analysts led by Matt Phipps, who rate Incyte at Outperform, called the news disappointing. They highlighted ...

Nvidia helped pull U.S. stock indexes higher after they stumbled in the morning on worries about escalations in the ...

Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Incyte shares slid after the drug maker paused trial enrollment for a hives ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Celldex Therapeutics ( (CLDX) ) has released its Q3 earnings. Here is a breakdown of the information Celldex Therapeutics presented to its ...

Incyte tumbled 10.5% after the biopharmaceutical company said it’s pausing enrollment in its ongoing study of a potential ...

KRIS AQUINO - The Queen of All Media took to social media a photo of the bouquet of flower sent for her by an anonymous ...